Table 1.

Basic characteristics of included studies

Author	Year	Country/region	Mean age (years)	Disease duration at anakinra start	Treatment arm	Study duration	Study quality score
Lequerré et al28	2008	France	38.1	7.8 years†	Anakinra 100 mg/day	17.5 months†	6
Nordström et al29	2012	Europe*	39 39	14 months‡ 19 months‡	Anakinra 100 mg/day DMARD treatment#	24 weeks 24 weeks	8
Cavalli et al30	2013	Italy	–	5 years†	Anakinra 100 mg/day	At least 24 months	4
Gerfaud-Valentin et al13	2014	France	36	4 months‡	Anakinra 100 mg/day	27.8 months†	7
Giampietro et al31	2013	France	33.3	9.3 years†	Anakinra 100 mg/day	23 months†	6
Laskari et al32	2011	Greece	32	7 months‡	Anakinra 100 mg/day	15 months‡	6
Iliou et al33	2013	Greece	38.3	3.5 months†	Anakinra 100 mg/day	7 years‡	6
Giampietro et al34	2010	France	40.6	9.4 years†	Anakinra 100 mg/day	30.7 months†	5

Notes:

^*Patients in Finland, Norway, and Sweden were included for study.

^†Mean time.

^‡Median time.

^#Six patients with methotrexate (10–25 mg weekly, oral), three patients with azathioprine (1–3 mg/kg/day, oral), and one patient with leflunomide (20 mg/day, oral).

Abbreviation: DMARD, disease-modifying antirheumatic drugs.